Table 1.
Characteristics of patients receiving neoadjuvant chemotherapy and total mastectomy stratified by AJCC stage
| Variable | AJCC clinical stage | p | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| IIB (N = 1031) | IIIA (N = 1215) | IIIB (N = 1003) | IIIC (N = 405) | |||
| Age | Mean (SD) | 50.1 (10.1) | 50.6 (10.4) | 54.3 (10.6) | 53.4 (11.1) | 0.0426 |
| Median (Q1, Q3) | 50 (43, 57) | 50 (44, 58) | 54 (47, 61) | 53 (46, 61) | ||
| 20-49 | 514 (49.9%) | 587 (48.3%) | 330 (32.9%) | 149 (36.8%) | < 0.0001 | |
| 50+ | 517 (50.1%) | 628 (51.7%) | 673 (67.1%) | 256 (63.2%) | ||
| Diagnosis year | 2007-2010 | 344 (33.4%) | 434 (35.7%) | 380 (37.9%) | 103 (25.4%) | < 0.0001 |
| 2011-2015 | 687 (66.6%) | 781 (64.3%) | 623 (62.1%) | 302 (74.6%) | ||
| CCI scores | 0 | 828 (80.3%) | 1000 (82.3%) | 835 (83.3%) | 339 (83.7%) | 0.6067 |
| 1 | 144 (14.0%) | 147 (12.1%) | 114 (11.4%) | 47 (11.6%) | ||
| 2+ | 59 (5.7%) | 68 (5.6%) | 54 (5.4%) | 19 (4.7%) | ||
| Differentiation | I | 65 (6.3%) | 76 (6.3%) | 63 (6.3%) | 16 (4.0%) | 0.4723 |
| II | 549 (53.2%) | 603 (49.6%) | 525 (52.3%) | 184 (45.4%) | ||
| III | 417 (40.5%) | 536 (44.1%) | 415 (41.4%) | 205 (50.6%) | ||
| NACT regimen | Taxanes | 376 (36.5%) | 477 (39.3%) | 346 (34.5%) | 191 (47.2%) | < 0.0001 |
| Anthracycline | 331 (32.1%) | 303 (24.9%) | 290 (28.9%) | 100 (24.7%) | ||
| Both | 246 (23.9%) | 366 (30.1%) | 320 (31.9%) | 106 (26.2%) | ||
| Neither | 78 (7.6%) | 69 (5.7%) | 47 (4.7%) | 8 (2.0%) | ||
| Nodal surgery | ALND | 837 (81.2%) | 1010 (83.1%) | 827 (82.5%) | 355 (87.7%) | 0.0559 |
| SLNB | 194 (18.8%) | 205 (16.9%) | 176 (17.5%) | 50 (12.3%) | ||
| Adjuvant PMRT | 657 (63.7%) | 954 (78.5%) | 739 (73.7%) | 346 (85.4%) | < 0.0001 | |
| Hormone receptor positive | 557 (54.0%) | 638 (52.5%) | 467 (46.6%) | 158 (39.0%) | < 0.0001 | |
| HER2 positive | 328 (31.8%) | 465 (38.3%) | 368 (36.7%) | 186 (45.9%) | < 0.0001 | |
| Academic hospital | Yes | 663 (64.3%) | 679 (55.9%) | 583 (58.1%) | 210 (51.9%) | < 0.0001 |
| No | 368 (35.7%) | 536 (44.1%) | 420 (41.9%) | 195 (48.1%) | ||
| Response of AJCC-stages ratio | pCR | 70 (6.8%) | 76 (6.3%) | 58 (5.8%) | 27 (6.7%) | < 0.0001 |
| Downstages | 416 (40.3%) | 529 (43.5%) | 543 (54.1%) | 251 (62.0%) | ||
| Equal-stages | 207 (20.1%) | 359 (29.5%) | 248 (24.7%) | 127 (31.4%) | ||
| Upstages | 338 (32.8%) | 251 (20.7%) | 154 (15.4%) | 0 (0%) | ||
| Response of T-stages ratio | T-pCR | 78 (7.6%) | 91 (7.5%) | 61 (6.1%) | 41 (10.1%) | < 0.0001 |
| Downstages | 424 (41.1%) | 738 (60.7%) | 635 (63.3%) | 234 (57.8%) | ||
| Equal-stages | 444 (43.1%) | 343 (28.2%) | 307 (30.6%) | 122 (30.1%) | ||
| Upstages | 85 (8.2%) | 43 (3.5%) | 0 (0%) | 8 (2.0%) | ||
| Response of N-stages ratio | N-pCR | 281 (27.3%) | 336 (27.7%) | 255 (25.4%) | 100 (24.7%) | < 0.0001 |
| Downstages | 0 (0%) | 119 (9.8%) | 74 (7.4%) | 178 (43.9%) | ||
| Equal-stages | 411 (39.9%) | 382 (31.4%) | 352 (35.1%) | 127 (31.4%) | ||
| Upstages | 339 (32.9%) | 378 (31.1%) | 322 (32.1%) | 0 (0%) | ||
| Mean follow-up time, months (SD) | 63.6 (31.0) | 60.6 (30.4) | 57.6 (30.5) | 52.7 (28.6) | < 0.0001 | |
| Death | 190 (18.4%) | 327 (26.9%) | 339 (33.8%) | 148 (36.5%) | < 0.0001 | |
| Locoregional recurrence | 70 (6.8%) | 89 (7.3%) | 88 (8.8%) | 38 (9.4%) | < 0.0001 | |
| Distant metastasis | 228 (22.1%) | 341 (28.1%) | 326 (32.5%) | 138 (34.1%) | < 0.0001 | |
PMRT, postmastectomy radiation therapy; T, tumor; N, nodal; NACT, neoadjuvant chemotherapy; TM, total mastectomy; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; pCR, pathologic complete response; ALND, axillary lymph node dissection; SNLB, sentinel lymph node biopsy; SD, standard deviation; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; ypT, postchemotherapy pathologic tumor stages; ypN, postchemotherapy pathologic nodal stages; IQR, interquartile range; T-pCR, pathologic complete response in the breast; N-pCR, pathologic complete response in regional lymph nodes.